Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | MET | P08581 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ICMT | O60725 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5444227 | 0.98 | PTPN7 (0.44) | PTPN7CNR2METALDH1A1SMN1; SMN2 | |
| SCHEMBL5441547 | 0.98 | PTPN7 (0.47) | PTPN7CNR2METALDH1A1SMN1; SMN2 | |
| SCHEMBL14412060 | 0.96 | PTPN7 (0.46) | PTPN7CNR2METKDM4E | |
| SCHEMBL5463119 | 0.92 | PTPN7 (0.42) | PTPN7CNR2MAOB | |
| SCHEMBL5451967 | 0.92 | CNR2 (0.50) | PTPN7CNR2METPDE10ATHRB | |
| SCHEMBL5448680 | 0.92 | CNR2 (0.46) | CNR2ALDH1A1PDE10AKDM4ETHRB | |
| SCHEMBL5451197 | 0.91 | PTPN7 (0.40) | PTPN7CNR2METALDH1A1PDE10A | |
| SCHEMBL5448149 | 0.90 | MET (0.40) | PTPN7CNR2METPDE10A | |
| SCHEMBL5462928 | 0.90 | CNR2 (0.44) | PTPN7CNR2METALDH1A1SMN1; SMN2 | |
| SCHEMBL5446864 | 0.89 | CNR2 (0.45) | CNR2ALDH1A1PDE10AKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | PTPN7 592/4885CNR2 106/4885MET 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.